Dobashi Kazushige, Singh Inderjit, Orak John K, Asayama Kohtaro, Singh Avtar K
Department of Pediatrics and Pathology, Medical University of South Carolina, Charleston, SC 29425, USA.
Mol Cell Biochem. 2002 Nov;240(1-2):9-17. doi: 10.1023/a:1020629020443.
Renal ischemia is of clinical interest because of its role in renal failure and also renal graft rejection. To evaluate the effect of the combination of N-acetylcysteine (NAC), a potent antioxidant, sodium nitroprusside (SNP), a nitric oxide donor, and phosphoramidon (P), an endothelin converting enzyme inhibitor, on tissue protection against ischemia-reperfusion injury, we studied the biochemical and morphological changes due to 90 min of renal ischemia-reperfusion in the rat model. Ninety min of ischemia caused very severe injury and the animals could not survive after 4 days without any treatment. Whereas, animals in the treated groups survived i.e. the NAC group (25%), NAC + SNP group (43%) and in the NAC + SNP + P group (100%), 2 weeks after 90 min of ischemia. A significant increase in the serum levels of creatinine and urea nitrogen was shown in the untreated group and to a much lesser extent in the treated group, especially in the NAC + SNP + P group. The protective effect was also supported by light microscopic studies on renal tissue sections. We also measured the activities of antioxidant enzymes in tissue homogenates. With the exception of Mn-superoxide dismutase, the activities of antioxidant enzymes (catalase, glutathione peroxidase, CuZn-superoxide dismutase) were decreased in the untreated kidney. The administration of NAC alone and NAC + SNP protected against the loss of activities. Treatment with a combination of NAC, SNP and P showed a synergistic effect as evidenced by the best protection. These results suggest that pre-administration of a combination of antioxidant (NAC) with endothelin derived vasodilators (sodium nitroprusside and Phosphoramidon) attenuates renal ischemia-reperfusion injury, e.g. in donor kidney for transplantation, by protecting cells against free radical damage.
肾缺血因其在肾衰竭以及肾移植排斥反应中的作用而具有临床研究意义。为了评估强效抗氧化剂N-乙酰半胱氨酸(NAC)、一氧化氮供体硝普钠(SNP)和内皮素转化酶抑制剂磷酰胺素(P)联合使用对组织抗缺血再灌注损伤的保护作用,我们在大鼠模型中研究了90分钟肾缺血再灌注所致的生化和形态学变化。90分钟的缺血造成了非常严重的损伤,未经任何治疗的动物在4天后无法存活。然而,在缺血90分钟后2周,治疗组的动物存活了下来,即NAC组(25%)、NAC + SNP组(43%)和NAC + SNP + P组(100%)。未治疗组血清肌酐和尿素氮水平显著升高,而治疗组升高程度小得多,尤其是NAC + SNP + P组。肾组织切片的光学显微镜研究也支持了这种保护作用。我们还测量了组织匀浆中抗氧化酶的活性。除锰超氧化物歧化酶外,未治疗的肾脏中抗氧化酶(过氧化氢酶、谷胱甘肽过氧化物酶、铜锌超氧化物歧化酶)的活性降低。单独给予NAC和NAC + SNP可防止酶活性丧失。NAC、SNP和P联合治疗显示出协同效应,保护效果最佳。这些结果表明,抗氧化剂(NAC)与内皮素衍生的血管舒张剂(硝普钠和磷酰胺素)联合预先给药可减轻肾缺血再灌注损伤,例如在移植供肾中,通过保护细胞免受自由基损伤。